Oncolytic Cancer Therapies Market to Observe Immense Growth at a Massive CAGR of 33% by 2032 | DelveInsight

The oncolytic virus therapies market is expected to grow in the coming years. According to estimates, the United States will contribute the largest oncolytic virus therapies market share. It is important to note that Imlygic's debut did not result in significant commercial success in the melanoma market. Some of the main reasons for this novel therapy's insignificant revenues are its limitations, no statistically significant benefit in overall survival, and intense competition from immune checkpoint inhibitors due to their efficacy and manageable side effects.

LAS VEGAS, Oct. 10, 2022 /PRNewswire/ -- DelveInsight's Oncolytic Cancer Therapies Market Insights report includes a comprehensive understanding of current treatment practices, oncolytic cancer therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Oncolytic Cancer Therapies Market Report

• As per DelveInsight analysis, the oncolytic cancer therapies market size in the 7MM was approximately USD 122 million in 2021.
• As per the estimates, the total indication-wise target patient pool cases across 7MM were about 632K in 2021.
• Leading oncolytic cancer therapies companies such as Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others are evaluating novel oncolytic virus cancer therapies to improve the treatment landscape.
• The oncolytic cancer therapies in the pipeline include ONCOS-102, RP1 (Vusolimogene Oderparepvec), GL-ONC1, CAN-2409, DNX-2401 (Tasadenoturev), PEXA-VEC (Pexastimogene Devacirepvec; JX-594), G207, LOAd703, Lerapolturev (Formerly Known as PVSRIPO), CG0070, and others.
• Growth of oncolytic virus therapy in the market is expected to be driven by increased understanding of challenges and limitations in cancer therapy and continued studies of advances in recombinant oncolytic viruses.

Discover which therapies are expected to grab the significant oncolytic cancer therapies market share @Oncolytic Cancer Therapies Market Report

Oncolytic Cancer Therapies Overview

Oncolytic viruses are cancer treatments that use a native or reprogrammed virus with the ability to target and kill cancerous cells. They are a new class of cancer agents that promote tumor regression through preferential replication in tumor cells, induction of immunogenic cell death, and stimulation of host antitumor immunity. These are experimental cancer treatments that aim to use the inherent properties of viruses to aid in the fight against cancer. These non-human viruses replicate in cancer cells while largely ignoring healthy cells.

Oncolytic viruses have the ability to generate virions quickly and genetically engineer additional genes that promote antitumor immunity, increase tumor cell susceptibility to ionizing radiation or cytotoxic chemotherapy, and increase patient safety.

Oncolytic Cancer Therapies Epidemiology Segmentation

According to DelveInsight estimates, there were around 694K patients in the neoadjuvant/adjuvant settings of selected cancer types in the 7MM in 2021.

In 2021, the total target patient pool for oncolytic virus cancer therapies across the EU5 was estimated to be around 270K.

The oncolytic cancer therapies market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident cases of selected cancer types
• Target Patient Pool of Oncolytic Virus Cancer Therapy by Cancer Types
• Total Treated cases by the line of therapies

Download the report to understand which factors are driving oncolytic cancer therapies epidemiology trends @Oncolytic Cancer Therapies Epidemiological Insights

Oncolytic Cancer Therapies Treatment Market 

Cancer treatment options currently available include immunotherapy, radiotherapy, chemotherapy, targeted drug therapy, hormone therapy, and others. However, not all patients benefit from these therapies because patients develop resistance to them.

The current immunotherapy paradigm's major flaw is its emphasis on adaptive immunity at the expense of immunity. While some of these obstacles can be overcome with combination systemic treatments such as dual checkpoint inhibition, the side effects of such multidrug regimens can be severe.

To combat such a scenario, oncolytic virus cancer therapy appears to be the most appealing and promising approach, with dual mechanisms of action: direct oncolysis and immune-mediated anticancer effect and overcoming resistance through an alternative cell-killing mechanism.

Amgen's Imlygic (T-Vec), the first oncolytic virus, was approved by the US FDA in 2015 for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after the initial surgery. After a few months, in December 2015, the European Commission (EC) approved it for treating adults with unresectable melanoma that has spread regionally or distantly (Stage IIIB, IIIC, and IVM1a), with no bone, brain, lung, or other visceral diseases.

To know more about oncolytic viruses for cancer treatment, visit @Cancer Gene Therapy Clinical Trials 

Oncolytic Cancer Therapies Pipeline Therapies and Key Companies

• ONCOS-102: Targovax
• RP1 (Vusolimogene Oderparepvec): Replimune
• GL-ONC1: Genelux Corporation
• CAN-2409: Candel Therapeutics
• DNX-2401 (Tasadenoturev): DNAtrix
• PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen
• G207: Treovir
• LOAd703: Lokon Pharma AB
• Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology
• CG0070: CG Oncology

Learn more about the FDA-approved oncolytic cancer therapies @Oncolytic Virus Therapy 

Oncolytic Cancer Therapies Market Dynamics

The approval of several drugs targeting different cancer indications is expected to change the dynamics of the oncolytic virus therapies market in the coming years. As per our estimates, the United States will have the largest oncolytic virus therapies market share.

Moreover, oncolytic viruses have many advantages over other tumor immunotherapies, including high killing efficiency, precise targeting, fewer side effects or drug resistance, and low cost, fueling the oncolytic virus therapies market growth. Furthermore, as certain oncolytic viruses, such as Adeno oncolytic viruses, have demonstrated antitumor memory, they could be used as a cancer vaccine.

However, certain factors are affecting the growth of the oncolytic virus therapies market. Oncolytic viruses can infect healthy cells and stimulate overall immune activity, and they can sometimes cause the immune system to attack healthy cells. Moreover, there is a risk of infection. In addition, the ability to efficiently deliver OV particles to tumors remains a significant barrier to the oncolytic virus therapies market growth.

Furthermore, it is important to note that Imlygic's initial commercial success in the melanoma market was limited. The limitations of this novel therapy, the lack of a statistically significant benefit in overall survival, and intense competition from immune checkpoint inhibitors due to their efficacy and manageable side effects are some of the main reasons for its insignificant revenues in the oncolytic virus therapies market.

Scope of the Oncolytic Cancer Therapies Market Report

• Therapeutic Assessment: Oncolytic Cancer Therapies current marketed and emerging therapies
• Oncolytic Cancer Therapies Market Dynamics: Oncolytic Cancer Therapies market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Oncolytic Cancer Therapies Market Access and Reimbursement

Discover more about emerging oncolytic cancer therapies in development @Oncolytic Cancer Therapies Clinical Trials

Table of Contents

Related Reports

Oncolytic Virus Cancer Therapy Epidemiology Forecast

Oncolytic Virus Cancer Therapy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted oncolytic virus cancer therapy epidemiology in the 7MM.

Oncolytic Virus Cancer Therapy Pipeline

Oncolytic Virus Cancer Therapy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key oncolytic virus cancer therapy companies, including Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Amgen, Oncolys Biopharma, among others.

Oncology Drugs Market

Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, among others.

Intratumoral Cancer Therapies Market

Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key intratumoral cancer therapies companies, including Daiichi Sankyo, Amgen, Idera Pharmaceuticals, among others.

Liquid Biopsy in Cancer Diagnostics Market

Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, among others.

Metastatic Breast Cancer Pipeline

Metastatic Breast Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic breast cancer companies including Roche, RemeGen, SynCore Biotechnology, among others.

Other Trending Reports

Goitre Market |  Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight

Related Healthcare Blogs

Upcoming Oncological Drugs in 2022

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us
Shruti Thakur
info@delveinsight.com 
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg